Sionna Therapeutics, Inc.
SION evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SION—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SION
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cystic fibrosis, with no approved products and no revenue from product sales to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 2 clinical trials for Sionna Therapeutics, Inc..
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cystic fibrosis, with no approved products and no revenue from product sales to date.
- Sionna Therapeutics has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-08-06].
- The company will need substantial additional capital to support operations and pursue its growth strategy [sec_mda · as of 2026-08-06].
- As of 2026-06-30, Sionna reported cash & equivalents of $64.3M and a net loss of -$29.9M [sec].
- The company's future funding requirements depend on the type, number, scope, progress, and costs of preclinical studies and clinical trials, as well as manufacturing and regulatory review costs [sec_mda · as of 2026-08-06].
What works
- Sionna Therapeutics is actively advancing its pipeline of product candidates, with ongoing clinical trials and research activities [sec_mda · as of 2026-08-06].
- The company has a clear focus on developing therapies for cystic fibrosis, a well-defined therapeutic area with significant unmet medical need [sec_mda · as of 2026-08-06].
What to weigh
- Sionna Therapeutics has no approved products and has never generated revenue from product sales, making it entirely dependent on future clinical and regulatory success [sec_mda · as of 2026-08-06].
- The company will require substantial additional capital to fund its operations, and there is no guarantee that it will be able to raise such capital on favorable terms [sec_mda · as of 2026-08-06].
- Conducting preclinical studies and clinical trials is costly and uncertain, with timing and expenses varying significantly [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Sionna has no approved products and no product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 6, 2026
Future funding requirements depend on clinical trial and regulatory factors.
“Our future funding requirements will depend largely on: • the type, number, scope, progress, expansions, results, costs and timing of discovery, preclinical studies and clinical trials of our current and future product candidates; • the costs and timing of manufacturing for our current and future product candidates and commercial manufacturing; • the costs, timing and outcome of regulatory review of our current and future product candidates;”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Sionna has no products approved for sale and has never generated product revenue, relying entirely on future clinical and regulatory success [sec_mda · as of 2026-08-06].
- Need for substantial additional capital — The company will require substantial additional funding to support operations and growth, with no guarantee of availability [sec_mda · as of 2026-08-06].
- Uncertainty in clinical trials — Preclinical studies and clinical trials are costly and uncertain, with timing and expenses varying significantly [sec_mda · as of 2026-08-06].
What to watch
- Progress and results of ongoing clinical trials for Sionna's product candidates [sec_mda · as of 2026-08-06].
- Any updates on the company's ability to raise additional capital or secure partnerships [sec_mda · as of 2026-08-06].
- Regulatory milestones and interactions with health authorities regarding product candidates [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Sionna Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sionna Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
14.8 months
D/E 0.07 · 0% dilution
Lead: Phase 2
8 candidates
No upcoming catalysts tracked
0 buys · 24 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
119
Total value held
$1.43B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 9,905,045 | $397.1M |
| orbimed advisors llc | 3,530,702 | $141.5M |
| viking global investors lp | 3,195,181 | $128.1M |
| enavate sciences gp, llc | 2,478,030 | $99.3M |
| vanguard capital management llc | 2,058,994 | $82.5M |
| jennison associates llc | 1,451,220 | $58.2M |
| perceptive advisors llc | 1,316,878 | $52.8M |
| blackrock, inc. | 1,295,867 | $52.0M |
| citadel advisors llc | 1,166,931 | $46.8M |
| deerfield management company, l.p. | 970,590 | $38.9M |
Showing top 10 of 119 institutional holders of Sionna Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 14.0%
- Days to cover
- 9.8
- Shares short
- 3,799,971
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SION short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cystic fibrosis, with no approved products and no revenue from product sales to date.
What is Sionna Therapeutics, Inc.'s lead drug candidate?
Sionna Therapeutics, Inc.'s most advanced tracked candidate is galicaftor (Phase 2) for Cystic fibrosis.
Who is the CEO of Sionna Therapeutics, Inc.?
Mr. Michael Cloonan M.B.A. is the chief executive officer of Sionna Therapeutics, Inc. (SION).
Where is Sionna Therapeutics, Inc. headquartered?
Sionna Therapeutics, Inc. (SION) is headquartered in Waltham, MA, United States.
What therapeutic areas does Sionna Therapeutics, Inc. focus on?
Sionna Therapeutics, Inc. develops therapies across Rare Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.